Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2019, Vol. 46 Issue (4): 637-640    DOI: 10.12891/ceog4580.2019
Case Report Previous articles | Next articles
A novel treatment of severe dysmenorrhea due to adenomyosis: a case series of 3 infertile patients treated with dopamine agonist and in vitro fertilization-embryo transfer resulting in successful pregnancy
H. Kwon1, J.E. Shin1, *(), H. Kim1
1Department of Obstetrics and Gynecology and Fertility Center of CHA Bundang Medical Center, CHA University, Seoul, South Korea
Download:  PDF(479KB)  ( 222 ) Full text   ( 7 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Few therapies for adenomyosis are available for infertile patients with reduced ovarian reserve. Previous studies investigating dopamine agonists on endometriosis have reported a reduction of peritoneal endometriosis and nerve fiber density. The present authors hypothesized that this treatment could be applied to patients with adenomyosis. They describe three infertile patients who were treated with dopamine agonists for adenomyosis. All three patients had severe dysmenorrhea due to adenomyosis with a numerical rating scale (NRS) of 10. Patients were treated twice daily with 2.5 mg bromocriptine or twice weekly with 0.5 mg cabergoline for a duration ranging from four weeks to four months. After treatment, the NRS of dysmenorrhea was about 1~2 and all patients became pregnant via in vitro fertilization-embryo transfer. Dopamine agonist acts as neurotransmitter that binds to the D2 receptor on endothelial cells and promotes VEGFR-2 endocytosis, thereby reducing immature blood vessels, nerve fiber density, and resident macrophage of endometriosis.

Key words:  Adenomyosis      Infertility dopamine agonist      Dysmenorrhea      Nerve fiber density     
Published:  10 August 2019     
*Corresponding Author(s):  J.E. SHIN     E-mail:  1219annie@cha.ac.kr

Cite this article: 

H. Kwon, J.E. Shin, H. Kim. A novel treatment of severe dysmenorrhea due to adenomyosis: a case series of 3 infertile patients treated with dopamine agonist and in vitro fertilization-embryo transfer resulting in successful pregnancy. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(4): 637-640.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog4580.2019     OR     https://ceog.imrpress.com/EN/Y2019/V46/I4/637

[1] Anjeza Xholli, Anna Biasioli, Giovanni Grandi, Angelo Cagnacci. Dienogest-based hormonal contraception induced changes in the ultrasound presentation of the uterus and menstrual pain[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1186-1192.
[2] Su-Xian Zhang, Lu Wu, You-Fang Hou, Bo Yan, Shao-Yan Yang, Li-Hua Yang, Qing-Hua Zhao. Hemoperitoneum caused by bleeding of adenomyosis: a case report[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 444-447.
[3] Ja Young Kim, Yun Gyu Song, Chang-Woon Kim, Moon Ok Lee. Uterine artery embolization using gelatin sponge particles for symptomatic focal and diffuse adenomyosis[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 59-65.
[4] Xiao-Cen Niu, Li-Hua Zhu, Zhi-Da Qian, Li-Li Huang. Disseminated intravascular coagulation developed after suction curettage in an adenomyosis patient: a case report and literature review[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 189-193.
[5] Yan-Bing Xiao, Meng Mou, Heng-Fang Gu, Hui-Xing Li, Meng-Yuan You, Zhi-Gang Liang, Lei Han. The impact of major uterine wall resection and reconstruction of the uterus (MURU) on uterine hemodynamics and ovarian function in patients with adenomyosis: a clinical study[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 132-137.
[6] S.Y. Song, G.W. Lee, J.B. Yang, D.E. Kim, D.B. Park, H.J. Yoo. Septic shock caused by abscess formation inside cystic adenomyosis after responsive treatment of pelvic inflammatory disease[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(6): 983-987.
[7] J.H. Check, D. Check, R. Cohen. A novel effective treatment for menière’s disease – dextroamphetamine sulfate[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 807-809.
[8] H. Takagi, S. Yamada, J. Sakamoto, S. Fujita, T. Sasagawa. Hemostatic effects of kyukikyogaito in dienogest treatment[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 560-564.
[9] H.S. Song, Y.A. Kim. Placenta percreta at 33 weeks of gestation after laparoscopic radiofrequency ablation for adenomyosis and Conservative Surgical Treatment: A case report and review of literature[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 600-603.
[10] A. Pontis, L. Nappi, F. Sorrentino, S. Angioni. Differential diagnosis of adenomyosis: the role of hysteroscopy and laparoscopy[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(4): 511-515.
[11] H. Takagi, J. Sakamoto, T. Sasagawa. Long-term treatment of endometriosis with dienogest for up to five years[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(3): 398-402.
[12] Jae-Seong Lee, Tae-Eung Kim, Jang Heub Kim, Byung Joon Park. Unintended pregnancies with term delivery following ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation of uterine fibroid and adenomyosis[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(6): 842-844.
[13] Sha A Dai Ti, Wu Fu Er, Zhao Lei, A Yi Nu Er, Mai Su Ti, Gu Li Na, A Ba Bai Ke Li. Clinical evaluation of three methods in the treatment of adenomyosis[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(4): 508-512.
[14] Ju-Qi Ma, Chun-Fen Guo, Ayshamgul Hasim. Clinical efficacy of levonorgestrel releasing intrauterine system for the treatment of adenomyosis in perimenopausal women[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(3): 387-390.
[15] H. Takagi, T. Sasagawa, Y. Osaka. Confirmation of menopause based on changes in follicle-stimulating hormone levels in patients who were administered dienogest[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 312-315.
No Suggested Reading articles found!